Abstract Introduction: Glioblastoma multiforme (GBM) is the most common and malignant of adult glial tumors. Despite best standard of care including surgical resection, radiation and chemotherapy (e.g. temozolomide), the median survival remains approximately 12 – 15 months, with fewer than 25% of patients surviving up to 2 years and less than 10% of patients surviving up to 5 years. We sought to identify a preliminary set of baseline tissue-based DNA and protein features which may reflect growth mechanisms responsible for disease progression, and overall survival (OS). Methods: Formalin fixed paraffin embedded specimens from 54 patients (44 Astrocytoma (including 14 GBM), 6 oligodendroglioma and 4 mixed) with outcome data and a median follow-up of 3 years were evaluated using dual-color DNA FISH for PTEN and EGFR. A multispectral immunofluorescent (IF) assay was used as previously described (Cordon-Cardo et al., 2007) to evaluate Ki67, PTEN, and P-AKT. Feature performance was univariately assessed using Kaplan-Meier survival curves. Results: A >10% Loss of heterozygosity (LOH) for PTEN (p-value <0.05) but not EGFR amplification / polysomy was associated with decreased OS in the total cohort. By comparison, the combination of PTEN LOH and EGFR amplification/polysomy in the GBM-only group (n=12, complete data files) was associated with improved survival (p-value 0.03). By quantitative IF, increasing levels of KI67 were associated with shortened OS (p-value 0.004) in the total cohort. Conclusions: The incorporation of DNA FISH and quantitative IF is useful for developing a biologic baseline for understanding disease course in malignant gliomas. PTEN LOH and EGFR amplification / polysomy in GBM may suggest a pathway mechanism for favorable response. Citation Information: Clin Cancer Res 2010;16(7 Suppl):A40